Recap: Reata Pharmaceuticals Q4 Earnings
Shares of Reata Pharmaceuticals (NASDAQ:RETA) were unchanged after the company reported Q4 results.
Quarterly Results
Earnings per share increased 21.38% over the past year to ($1.25), which beat the estimate of ($2.16).
Revenue of $3,192,000 rose by 19.46% year over year, which beat the estimate of $1,440,000.
Looking Ahead
Reata Pharmaceuticals hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Details Of The Call
Date: Mar 01, 2021
Time: 08:30 AM
Technicals
52-week high: $209.91
52-week low: $88.17
Price action over last quarter: down 33.78%
Company Profile
Reata Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing therapeutics to address serious and life-threatening diseases by targeting molecular pathways. The company's product in the pipeline include bardoxolone methyl; Omaveloxolone and others.
Posted-In: BZI-RecapsEarnings News